Literature DB >> 28431668

GLP-1 receptor agonists in NAFLD.

J-M Petit1, B Vergès2.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of the disease. Currently, the only validated treatment for NAFLD is weight loss. A number of studies of animal models and human trials have evaluated the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on liver fat content and suggest that the treatment could represent a new alternative for NAFLD management. In this review, our focus is on the main studies regarding the effects of GLP-1RAs on NAFLD. Also, the mechanisms that might explain their beneficial effects on liver diseases are analyzed.
© 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Fibrosis; GLP-1 receptor agonists; Non-alcoholic fatty liver disease; Steatosis; type 2 diabetes

Mesh：

Substances：

Year:  2017        PMID： 28431668     DOI： 10.1016/S1262-3636(17)30070-8

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN： 1262-3636            Impact factor:   6.041


  14 in total

1.  SCFAs-Induced GLP-1 Secretion Links the Regulation of Gut Microbiome on Hepatic Lipogenesis in Chickens.

Authors:  Jian-Mei Zhang; Yin-Shuang Sun; Li-Qin Zhao; Tian-Tian Chen; Mei-Na Fan; Hong-Chao Jiao; Jing-Peng Zhao; Xiao-Juan Wang; Fu-Chang Li; Hai-Fang Li; Hai Lin
Journal:  Front Microbiol       Date:  2019-09-26       Impact factor: 5.640

Review 2.  Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease.

Authors:  Xiaoyan Li; Hua Wang
Journal:  Cell Biosci       Date:  2020-12-07       Impact factor: 7.133

Review 3.  Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides.

Authors:  L Kořínková; V Pražienková; L Černá; A Karnošová; B Železná; J Kuneš; Lenka Maletínská
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-26       Impact factor: 5.555

Review 4.  GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects.

Authors:  Xin Zhao; Minghe Wang; Zhitong Wen; Zhihong Lu; Lijuan Cui; Chao Fu; Huan Xue; Yunfeng Liu; Yi Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-23       Impact factor: 5.555

Review 5.  Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases.

Authors:  Wei Peng; Rui Zhou; Ze-Fang Sun; Jia-Wei Long; Yong-Qiang Gong
Journal:  Aging Dis       Date:  2022-04-01       Impact factor: 6.745

Review 6.  Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials.

Authors:  James J Connolly; Kohtaro Ooka; Joseph K Lim
Journal:  J Clin Transl Hepatol       Date:  2018-06-28

7.  Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study.

Authors:  Niina Matikainen; Sanni Söderlund; Elias Björnson; Kirsi Pietiläinen; Antti Hakkarainen; Nina Lundbom; Marja-Riitta Taskinen; Jan Borén
Journal:  Diabetes Obes Metab       Date:  2018-09-04       Impact factor: 6.577

Review 8.  Abnormal metabolic processes involved in the pathogenesis of non-alcoholic fatty liver disease (Review).

Authors:  Mingmei Shao; Zixiang Ye; Yanhong Qin; Tao Wu
Journal:  Exp Ther Med       Date:  2020-08-28       Impact factor: 2.447

Review 9.  The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.

Authors:  Qian Song; Xiang Zhang
Journal:  Biomedicines       Date:  2022-02-23

Review 10.  Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention.

Authors:  Danny Orabi; Nathan A Berger; J Mark Brown
Journal:  Cancers (Basel)       Date:  2021-07-11       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.